X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209923
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209813
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216001
https://www.cnbctv18.com/market/stocks/zydus-lifesciences-gets-usfda-nod-for-tofacitinib-tablets-16226171.htm
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-tofacitinib-tablets-46350.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209829
https://www.fiercebiotech.com/biotech/vyne-swings-behind-bet-inhibitors-seeks-partner-failed-eczema-drug
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217299
https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/
https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/
https://endpts.com/ema-limits-use-of-jak-inhibitors-for-at-risk-groups-in-wake-of-safety-concerns/
https://labblog.uofmhealth.org/lab-report/tofacitinib-shows-promise-scleroderma-patients-researchers-are-optimistic-for-next-phase
https://www.fiercepharma.com/pharma/biora-spin-xeljanz-nearing-clinic-posts-data-its-targeted-gut-drug-delivery-device
https://endpts.com/crowded-rheumatoid-arthritis-category-gets-jak-reality-check-while-tnf-stalwarts-continue-to-dominate-study/
https://endpts.com/ema-initiates-safety-review-on-jak-inhibitors-galapagos-woes-continue-as-it-terminates-latest-study/
https://www.fiercepharma.com/pharma/bristol-s-next-gen-autoimmune-med-not-just-another-jak-drug-exec-says
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-challenge-for-tofacitinib-oral-solution-1641964331.pdf
https://www.fiercepharma.com/marketing/held-up-fda-rulings-start-rolling-out-for-abbvie-s-rinvoq-pfizer-s-xeljanz-as-jak-safety
https://www.streetinsider.com/Corporate+News/AbbVies+%28ABBV%29+Label+for+RINVOQ+for+the+Treatment+of+Rheumatoid+Arthritis+Will+Include+Additional+Cardiac+Risk+Info/19308717.html
https://www.fiercepharma.com/marketing/eli-lilly-olumiant-long-term-safety-data-rheumatoid-arthritis-jak-class-safety-scrutiny
https://www.fiercepharma.com/pharma/dangling-rinvoq-fda-safety-warning-jak-inhibitors-abbvie-ceo-holds-back-confirmation-peak
https://www.fiercepharma.com/pharma/pfizer-snags-atopic-dermatitis-nod-for-xeljanz-follow-up-cibinqo-uk-first-amid-fda-class
http://www.pharmafile.com/news/587553/nice-recommends-pfizer-s-xeljanz-juvenile-idiopathic-arthritis
https://www.nice.org.uk/news/article/nice-recommends-treatment-for-people-with-juvenile-idiopathic-arthritis
https://www.pharmaceutical-technology.com/features/jak-inhibitors-fda-safety/
https://news.bloomberglaw.com/ip-law/pfizer-teva-settle-patent-suit-over-blockbuster-drug-xeljanz
https://endpts.com/fda-warns-of-heart-related-events-cancer-blood-clots-and-death-for-jak-inhibitors/
https://endpts.com/abbvies-stock-and-next-megablockbuster-take-hits-following-new-jak-warnings-from-fda/
https://www.fiercepharma.com/pharma/pfizer-s-arthritis-drug-xeljanz-shows-lifesaving-benefits-hospitalized-covid-19-patients
https://www.businesswire.com/news/home/20210616005998/en/Data-Published-in-New-England-Journal-of-Medicine-Shows-Pfizer%E2%80%99s-Tofacitinib-Meets-Primary-Endpoint-in-Brazilian-Study-in-Patients-Hospitalized-with-COVID-19-Pneumonia
https://www.fiercepharma.com/marketing/incyte-latest-to-fall-victim-to-jak-scrutiny-as-fda-pushes-back-jakafi-review-gvhd
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212943
http://www.pmlive.com/pharma_news/fda_considers_new_safety_warnings_for_pfizers_jak_inhibitor_xeljanz_1362988
https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis
https://www.fiercepharma.com/marketing/fda-weighs-harsher-sanctions-against-pfizer-s-xeljanz-heels-trial-raised-safety-red-flags
https://endpts.com/pfizers-xeljanz-flunks-its-post-marketing-safety-study-renewing-harsh-questions-for-jak-class/
https://www.forbes.com/sites/rachelsandler/2020/10/01/internal-memo-pfizer-ceo-slams-politicization-of-vaccine-development-during-presidential-debate/#3bb9cda245e3
https://www.raps.org/news-and-articles/news-articles/2020/9/fda-roundup-nucala-fetroja-xeljanz
https://seekingalpha.com/news/3617819-fda-approves-pfizers-xeljanz-for-polyarticular-course-juvenile-idiopathic-arthritis
https://www.biospace.com/article/releases/u-s-fda-approves-pfizer-s-xeljanz-tofacitinib-for-the-treatment-of-active-polyarticular-course-juvenile-idiopathic-arthritis/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212943
https://endpts.com/icer-criticizes-cost-of-8-targeted-immune-modulators-for-uc-recommending-some-deep-discounts/
https://endpts.com/top-biotech-analyst-projects-a-gloomy-outlook-for-pfizers-jak-portfolio/
https://www.fiercepharma.com/pharma/pfizer-may-have-a-lot-going-immunology-but-all-its-drugs-could-be-beaten-by-rivals-analyst
Market Place
Share 
